Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 63629-9295 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
chemical-structure - chemical structure
figure-1 - figure 1
figure-2 - figure 2
The figure shows the Mean Change from Baseline in IPSS Total Symptom Score for two groups: Placebo (N=167) and Alfuzosin hydrochloride extended-release tablets (N=170). The X-axis shows the days of treatment (0, 28, 56, and 84), and the Y-axis represents the IPSS Total Symptom Score. The asterisks indicate a statistically significant difference (p<0.001) between the two groups. No other information is available from this text.*
figure-3 - figure 3
The given text represents a figure with the Mean Change from Baseline in IPSS Total Symptom Score for Trial 2. The data is shown for 28 and 56 days of treatment with Placebo (N=152) and Alfuzosin hydrochloride extended-release tablets (N=137). The figure also indicates that the difference between the two treatments is statistically significant (p < 0.01) at both timepoints.*
figure-4 - figure 4
The figure shows the mean change from baseline in IPSS Total Symptom Score for Trial 3, comparing placebo treatment to treatment with Aituzosin hydrochloride extended-release tablets. The study involved 150 individuals in the placebo group and 151 individuals receiving the medication. Treatment lasted for 28 days and a statistically significant difference was observed between the groups.*
figure-5 - figure 5
This is a chart that displays the mean change in peak urine flow rate (mL/s) between a placebo group (N=167) and a group taking Alfuzosin hydrochloride extended-release tablets (N=170) over a period of 28 to 56 days of treatment. The chart shows a significant difference between the two groups, with the group taking the tablets having a greater mean change in peak urine flow rate.*
figure-6 - figure 6
The text is a graph titled "Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2" which compares the effectiveness of Atuzosin hydrochloride extended-release tablets to a placebo. The graph shows the results for 147 people who took the placebo and 136 people who took the tablets for a duration of 84 days. There was statistically significant improvement in peak urine flow rate among those who took the tablets compared to the placebo.*
figure-7 - figure 7
The text represents a figure showing the mean change from baseline in peak urine flow rate (in mL/s) for a trial (Trial 3) comparing a placebo group (N=150) with a group that received an extended-release tablet of alfuzosin hydrochloride (N=151) over a treatment period of 84 days. The figure also indicates that the statistical analysis found no significant difference (p > 0.05) between the two groups.*
Label - lbl636299295
Alfuzosin Hydrochloride is a medication that comes in extended-release tablet form with 10mg strength. Each tablet should be dispensed in a tightly sealed container in order to protect the medication from light and moisture, and should be stored at room temperature. The medication should not be given to children and should be dispensed with relevant patient information by a pharmacist. The usual dosage is to be determined by package insert. The NDC number of the medication is 63629-9295-1.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.